Navigation Links
Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting
Date:10/27/2008

POT-4 is the first complement inhibitor to be tested in AMD patients

LOUISVILLE, Ky., Oct. 27 /PRNewswire/ -- Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today that the Company will be presenting its ASaP Phase I clinical data for its leading drug candidate, POT-4, during the Retina Subspecialty Day at the American Academy of Ophthalmology (AAO) Annual Meeting in Atlanta, GA, on November 7, 2008.

Cedric Francois, President and CEO of Potentia Pharmaceuticals, said, "POT-4 is the first of several complement inhibitors that will ultimately be tested in macular degeneration. The role of complement in this disease was established in 2005 as the first breakthrough discovery resulting directly from the human genome project. If complement inhibition is successful at treating macular degeneration, it would be the first of hopefully many new drugs born out of the human genome project, and usher in an era of improved healthcare for millions of patients."

Dr. Philip J. Rosenfeld, M.D., Ph.D., Professor of Ophthalmology at the Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine in Miami, FL, and a clinical investigator in the study, will present the data on Potentia's behalf.

POT-4 is a complement inhibitor, which shuts down the complement activation cascade that could otherwise lead to local inflammation, tissue damage and upregulation of angiogenic factors such as vascular endothelial growth factor (VEGF) in the eye. Based on this mechanism of action, POT-4 holds the potential to be effective against both dry and wet AMD. POT-4 has shown early positive safety results in its Phase I study.

For more information on the presentation at AAO:

Title: Complement C3 Inhibitor POT-4 for AMD

When: Friday, November 7 at 9:01 AM EST

Location: Hall A-3 Session Room

Se
'/>"/>

SOURCE Potentia Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
2. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
3. Gladstone scientists uncover potential mechanism of memory loss in Alzheimers disease
4. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
5. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
6. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
7. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
8. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
9. Discovery of creator gene for cerebral cortex points to potential stem cell treatments
10. Research Using Thermo Fisher Scientific RNA-Interference Technology Unveils Potential New Targets for HIV Drugs
11. Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  Array BioPharma Inc. (NASDAQ: ARRY ) ... with Novartis Pharma AG to acquire worldwide rights to ... development.  This agreement is conditional on the closing of transactions ... 2014, which are expected to close in the first ...
(Date:1/22/2015)... Md. (PRWEB) January 22, 2015 ... its new UV-1280 multipurpose UV-visible spectrophotometer. Offering wavelength ... high-quality instrument is ideal for applications in a ... life science. , The user-friendly UV-1280 enables intuitive ...
(Date:1/22/2015)... Jan. 22, 2015  Transwestern | RBJ today announces the firm ... space for Shire a leading biopharmaceutical company, at Two Ledgemont ... RBJ,s Robert Richards , president, and Brian Cohen ... the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... Johnston, RI (PRWEB) January 22, 2015 ... State , The growing team of brand-neutral, independent consultants, ... CIO Philip Rogers explained that over the years, his ... including , Moroso, Town of Plainfield, as well as ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2
... fly . . . A prototype ... demonstrate a technology that could one day play a ... bench-scale prototype developed at Oak Ridge National Laboratory is ... to wirelessly charge stationary and moving vehicles. "Our laboratory ...
... Nov. 5, 2010 Metamark Genetics, Inc., a privately ... of Mark R. Straley as the company,s President, Chief ... Directors. Kenneth E. Weg, a Metamark co-founder who previously ... Chairman of the Board of Directors. Mr. ...
... SAN DIEGO, Nov. 5, 2010 Halozyme Therapeutics, ... company developing and commercializing products targeting the ... and drug delivery markets, today reported financial results ... (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO ) ...
Cached Biology Technology:Story tips from the Department of Energy's Oak Ridge National Laboratory, November 2010 2Story tips from the Department of Energy's Oak Ridge National Laboratory, November 2010 3Metamark Genetics, Inc. Announces New Chief Executive Officer 2Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 2Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 3Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 4Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 5Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 6Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 7
(Date:12/22/2014)... 2014  The 2014 Holiday Season may be the brightest ... reports that the long anticipated floodgates for consumer biometrics ... for smart phones, tablets, and wearable mobile devices that ... billion users with nearly 4.8 billion biometric devices by ...
(Date:12/19/2014)... and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has announced the ... Security Systems Market" report to their offering. ... perimeter security market is estimated to grow at a CAGR ... holds a larger share in this market, Canada ...
(Date:12/19/2014)... 2014   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... protein helps a cell bypass damage when making new ... they also discovered that this protein, an enzyme called ... sequence that later might cause the cell to become ... Ohio State University 's Comprehensive Cancer Center are described ...
... the Yerkes National Primate Research Center, Emory University, have ... hands, feet and limbs more flexibly than they do ... human language began with gestures as the gestural origin ... current issue of the Proceedings of the National Academy ...
... red tomatoes get their rich color from lycopene, a ... special variety of orange-colored tomatoes provide a different form ... use. , Researchers found that eating spaghetti covered in ... caused a noticeable boost in this form of lycopene ...
Cached Biology News:Protein averts cell suicide but might contribute to cancer 2Protein averts cell suicide but might contribute to cancer 3Ape gestures offer clues to the evolution of human communication 2Unique tomatoes tops in disease-fighting antioxidants 2Unique tomatoes tops in disease-fighting antioxidants 3
EoProbe Eosinophil Staining Kit, 1 Kit...
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
...
LabFax: Immunochemistry...
Biology Products: